Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

被引:0
|
作者
Thomas E. Hutson
Ram Ganapathi
Paul Elson
Tarek Mekhail
Thomas Olencki
G. Thomas Budd
Ronald M. Bukowski
机构
[1] Cleveland Clinic Foundation;,Experimental Therapeutics Program, Taussig Cancer Center
[2] Cleveland Clinic Foundation;,Clinical Pharmacology Laboratory, Taussig Cancer Center
[3] Cleveland Clinic Foundation,Department of Hematology and Medical Oncology, Taussig Cancer Center
来源
Investigational New Drugs | 2004年 / 22卷
关键词
vinorelbine; phase I clinical trial; microtubule poisons; multi-drug resistance (MDR);
D O I
暂无
中图分类号
学科分类号
摘要
The anti-epileptic diphenylhydantoin (DPH; Dilantin®) selectively enhances the in vitro cytotoxicity of vinca microtubule poisons in both parent sensitive and multi-drug resistant (MDR) human tumor cells. The in vivo clinical activity of this combination has not been fully evaluated. Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicities, and preliminary antitumor activity of the combination of intravenous (IV) bolus vinorelbine (VRL) and oral diphenylhydantoin (DPH) in patients (pts) with refractory solid tumors. Methods: Cohorts of 3–6 pts with refractory cancer were treated with escalating doses of weekly IV bolus VRL (I –20.0 mg/m2; II –22.5 mg/m2; III –25.0 mg/m2; IV –27.5 mg/m2; V –30.0 mg/m2; VI –32.5 mg/m2) combined with a fixed oral dose of DPH (400 mg/day) until MTD or progression. During each 35 day cycle, pts received DPH 400 mg/day administered orally on Days −6 to Day +22 and weekly IV bolus infusion of VRL on Days +1, +8, +15, and +22. The cohort treated at the MTD was expanded to further define toxicity. Results: A total of 25 evaluable pts. (9 men; 16 women) were treated with VRL and DPH at dose levels I (n = 5), II (n = 3), III (n = 2), IV (n = 3), V (n = 7) and VI (n = 5) in 5 week cycles over a 16 month period. Dose limiting toxicity occurred at dose level VI (VRL 32.5 mg/m2) and included grade 3 leukopenia (n = 2), grade 3 neutropenia (n = 1) and grade 4 neutropenia (n = 1) occurring within the first cycle of treatment. There were no responses, however 9 pts had stable disease of variable duration (8–56 weeks) and received a median of 2 cycles of treatment (range 2–14). Conclusion: Intravenous bolus administration of VRL and oral administration of a fixed dose of DPH was well tolerated according to the schedule reported here. Although there were no responses, several patients had prolonged disease stabilization. The recommended phase II dose of VRL when used in this combination is 30 mg/m2.
引用
收藏
页码:277 / 284
页数:7
相关论文
共 50 条
  • [21] A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
    Athanasios G. Pallis
    Vassilis Chandrinos
    Georgia Pavlakou
    Nikolaos Xenidis
    Ioannis Varthalitis
    Nikolaos Vardakis
    Lambros Vamvakas
    Emmanouel Kontopodis
    Maria Rovithi
    Vassilis Georgoulias
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1239 - 1245
  • [22] Phase I trial of pemetrexed disodium and vinorelbine (VNB) in patients with advanced malignancy.
    Clarke, S
    Millward, M
    Beale, P
    Bishop, J
    Childs, A
    Boyer, M
    De Souza, P
    ANNALS OF ONCOLOGY, 2000, 11 : 140 - 140
  • [23] Phase II Trial of Clofarabine With Topotecan, Vinorelbine, and Thiotepa in Pediatric Patients With Relapsed or Refractory Acute Leukemia
    Shukla, Neerav
    Kobos, Rachel
    Renaud, Thomas
    Steinherz, Laurel J.
    Steinherz, Peter G.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (03) : 431 - 435
  • [24] Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer
    Cohen, RB
    Mueller, SC
    Haden, K
    de Souza, P
    CANCER INVESTIGATION, 2000, 18 (05) : 422 - 428
  • [25] A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Saxman, S
    Mann, B
    Canfield, V
    Loehrer, P
    Vokes, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04): : 398 - 400
  • [26] Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
    Suekane, Shigetaka
    Nishitani, Masaaki
    Noguchi, Masanori
    Komohara, Yoshihiro
    Kokubu, Takako
    Naitoh, Masayasu
    Honma, Shigenori
    Yamada, Akira
    Itoh, Kyogo
    Matsuoka, Kei
    Kanayama, Hiroomi
    CANCER SCIENCE, 2007, 98 (12) : 1965 - 1968
  • [27] A phase I trial of personalised peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
    Suekane, S.
    Noguchi, M.
    Nishitani, M.
    Komohara, Y.
    Naitoh, M.
    Honma, S.
    Yamada, A.
    Kanayama, H.
    Itoh, K.
    Matsuoka, K.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 307 - 307
  • [28] A phase I II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma
    Viallet, J
    Brassard, MA
    Souhami, L
    Ayoub, J
    Del Vecchio, P
    Kreisman, H
    Guerra, J
    Gruber, J
    Langleben, A
    Hohneker, J
    Rousseau, P
    CANCER, 1999, 85 (12) : 2562 - 2569
  • [29] A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
    Park, Haeseong
    Williams, Kerry
    Trikalinos, Nikolaos A.
    Larson, Sarah
    Tan, Benjamin
    Waqar, Saiama
    Suresh, Rama
    Morgensztern, Daniel
    Van Tine, Brian A.
    Govindan, Ramaswamy
    Luo, Jingqin
    Lockhart, A. Craig
    Wang-Gillam, Andrea
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 337 - 347
  • [30] A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors
    Tsimberidou, Apostolia Maria
    Camacho, Luis H.
    Verstovsek, Srdan
    Ng, Chaan
    Hong, David S.
    Uehara, Cynthia K.
    Gutierrez, Catalina
    Daring, Shawn
    Stevens, Jan
    Komarnitsky, Philip B.
    Schwartz, Brian
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2009, 15 (14) : 4769 - 4776